Long-acting growth hormone in the management of GHD in France
Archives de Pédiatrie · 2024
DOI: 10.1016/j.arcped.2024.03.009 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archives de Pédiatrie, 2024. Verfasst von Agnès Linglart und 3 weiteren Autor:innen. Beteiligte Einrichtung: AP-HP, Paris Saclay University, INSERM U1185, Endocrinology and Diabetes for children, Reference Center for rare diseases of calcium and phosphate me…. Hauptthemen laut MEDLINE: Human Growth Hormone. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Pfizer France.
Abstract (Originalsprache)
Approximately 10,000 children in France with growth hormone deficiency (GHD) are being administered daily recombinant human growth hormone (rhGH). Although this treatment has long proved efficient for restoring children's growth and metabolism, daily injections of rhGH have a few limitations, such as difficulties in terms of adherence to treatment, which may compromise growth during childhood but also metabolism in adulthood. In addition to the disease burden and besides the adherence hurdles, the obligations related to daily injection have a negative impact on the quality of life of patients and their families. The hypothesis that injections administered at intervals of 1 week, or even 1 month, could improve compliance, reduce treatment discontinuations, and optimize quality of life and therapeutic effectiveness has led to the emergence of new long-acting growth hormone (LAGH). Recent access to LAGHs (somatrogon MA) on the European and French market will likely be followed by a high demand from the families concerned and may raise questions on their effectiveness, safety, and practical use. Numerous practical and practice-related points are needed to guide prescribing physicians while many concerns are still left unresolved (treatment effectiveness or ineffectiveness endpoints, long-term effectiveness, etc.). These issues can only be addressed in the future by compiling registries and conducting long-term real-world studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- AP-HP, Paris Saclay University, INSERM U1185, Endocrinology and Diabetes for children, Reference Center for rare diseases of calcium and phosphate metabolism, OSCAR network, Platform of expertise for rare diseases of Pa…
- Service d'Endocrinologie et Diabétologie Pédiatrique, Centre de Référence des Maladies Rares de la Thyroïde et des Récepteurs Hormonaux, Centre de Référence (constitutif) des Maladies Rares de l'Hypophyse, FIRENDO netwo…
- Hôpital Universitaire Necker Enfants Malades, Pediatric Endocrinology, Gynecology and Diabetology, Imagine Institute, INSERM U1163, Cochin Institute, INSERM U1016, Centre de référence des pathologies endocriniennes rare…
- Hospices Civils de Lyon, Service d'Endocrinologie et Diabétologie Pédiatriques et Centre PRISIS, Pathologies Rares de l'Insulino-Sécrétion et de l'Insulino-Sensibilité, FIRENDO network, Hôpital Femme-Mère-Enfant 69500,…
Förderung
- Pfizer France
Zitieren
APA
Linglart, A., Coutant, R., Polak, M., & Nicolino, M. (2024). Long-acting growth hormone in the management of GHD in France. Archives de Pédiatrie. https://doi.org/10.1016/j.arcped.2024.03.009
Vancouver
Linglart A, Coutant R, Polak M, Nicolino M. Long-acting growth hormone in the management of GHD in France. Archives de Pédiatrie. 2024. doi:10.1016/j.arcped.2024.03.009
BibTeX
@article{Linglart2024,
author = {Linglart, Agnès and Coutant, Régis and Polak, Michel and Nicolino, Marc},
title = {Long-acting growth hormone in the management of GHD in France},
journal = {Archives de Pédiatrie},
year = {2024},
doi = {10.1016/j.arcped.2024.03.009}
}
EUVIMED